gsk201408086k.htm

SECURITIES AND EXCHANGE COMMISSION 

Washington D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of 

the Securities Exchange Act of 1934

For period ending August 2014

(Name of registrant) 

980 Great West Road, Brentford, Middlesex, TW8 9GS

(Address of principal executive offices) 

Indicate by check mark whether the registrant files or

will file annual reports under cover Form 20-F or Form 40-F 

Form 20-F x Form 40-F 

Indicate by check mark whether the registrant by furnishing the

information contained in this Form is also thereby furnishing the

information to the Commission pursuant to Rule 12g3-2(b) under the

Securities Exchange Act of 1934. 

GlaxoSmithKline plc

Notification of Transactions of Directors, Persons Discharging Managerial Responsibility or Connected Persons

In accordance with DTR 3.1.4 R(1)(a) and (c) GlaxoSmithKline plc (GSK) was advised on 8 August 2014 of the following increase in the notional allocation of GSK American Depositary Shares (ADSs) on 7 August 2014, at a price of $46.35 per ADS, following the revaluation of the cash element of the notional investment held within the GSK 401K plan:

Director/PDMR	Number of ADSs
Mrs D P Connelly	2
Mr W C Louv	26
Dr M M Slaoui	19

Connected person	Number of ADSs
Dr K Slaoui	16

V A Whyte

Company Secretary

8 August 2014

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised. 

Date: August 08, 2014

By: VICTORIA WHYTE

------------------

Victoria Whyte

Authorised Signatory for and on

behalf of GlaxoSmithKline plc